Can newer anti-diabetic therapies delay the development of diabetic nephropathy?
Type 2 diabetes mellitus (T2DM) is progressive in nature and leads to hyperglycemia-associated microvascular and macrovascular complications. Diabetic nephropathy (DN) is one of the most prominent microvascular complication induced by T2DM and is characterized by albuminuria and progressive loss of...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Journal of Pharmacy and Bioallied Sciences |
| Subjects: | |
| Online Access: | http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2021;volume=13;issue=4;spage=341;epage=351;aulast=Aziz |
| _version_ | 1797995563909644288 |
|---|---|
| author | Sohail Aziz Siti Maisharah Sheikh Ghadzi Syed Azhar Syed Sulaiman Nur Hafzan Md Hanafiah Sabariah Noor Harun |
| author_facet | Sohail Aziz Siti Maisharah Sheikh Ghadzi Syed Azhar Syed Sulaiman Nur Hafzan Md Hanafiah Sabariah Noor Harun |
| author_sort | Sohail Aziz |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is progressive in nature and leads to hyperglycemia-associated microvascular and macrovascular complications. Diabetic nephropathy (DN) is one of the most prominent microvascular complication induced by T2DM and is characterized by albuminuria and progressive loss of kidney function. Aggressive management of hyperglycemia and hypertension has been found effective in delaying the development and progression of DN. Although the conventional antidiabetic treatment is effective in the earlier management of hyperglycemia, the progressive loss of beta cells ultimately needs the addition of insulin to the therapy. The emergence of newer antidiabetic agents may address the limitations associated with conventional antidiabetic therapies, which not only improve the glycemic status but also effective in improving cardio-renal outcomes. Nevertheless, the exact role of these agents and their role in minimizing diabetes progression to DN still needs elaboration. The present review aimed to highlights the impact of these newer antidiabetic agents in the management of hyperglycemia and their role in delaying the progression of diabetes to DN/management of DN in patients with T2DM. |
| first_indexed | 2024-04-11T10:02:31Z |
| format | Article |
| id | doaj.art-1885d8b261144597a1d432c9f3ce6e16 |
| institution | Directory Open Access Journal |
| issn | 0975-7406 |
| language | English |
| last_indexed | 2024-04-11T10:02:31Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Pharmacy and Bioallied Sciences |
| spelling | doaj.art-1885d8b261144597a1d432c9f3ce6e162022-12-22T04:30:19ZengWolters Kluwer Medknow PublicationsJournal of Pharmacy and Bioallied Sciences0975-74062021-01-0113434135110.4103/jpbs.jpbs_497_21Can newer anti-diabetic therapies delay the development of diabetic nephropathy?Sohail AzizSiti Maisharah Sheikh GhadziSyed Azhar Syed SulaimanNur Hafzan Md HanafiahSabariah Noor HarunType 2 diabetes mellitus (T2DM) is progressive in nature and leads to hyperglycemia-associated microvascular and macrovascular complications. Diabetic nephropathy (DN) is one of the most prominent microvascular complication induced by T2DM and is characterized by albuminuria and progressive loss of kidney function. Aggressive management of hyperglycemia and hypertension has been found effective in delaying the development and progression of DN. Although the conventional antidiabetic treatment is effective in the earlier management of hyperglycemia, the progressive loss of beta cells ultimately needs the addition of insulin to the therapy. The emergence of newer antidiabetic agents may address the limitations associated with conventional antidiabetic therapies, which not only improve the glycemic status but also effective in improving cardio-renal outcomes. Nevertheless, the exact role of these agents and their role in minimizing diabetes progression to DN still needs elaboration. The present review aimed to highlights the impact of these newer antidiabetic agents in the management of hyperglycemia and their role in delaying the progression of diabetes to DN/management of DN in patients with T2DM.http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2021;volume=13;issue=4;spage=341;epage=351;aulast=Azizddp4idiabetes progressiondiabetic nephropathyglucagon-like peptide-1 agonistnewer antidiabeticsperoxisome proliferator-activated receptors-γsglt-2i |
| spellingShingle | Sohail Aziz Siti Maisharah Sheikh Ghadzi Syed Azhar Syed Sulaiman Nur Hafzan Md Hanafiah Sabariah Noor Harun Can newer anti-diabetic therapies delay the development of diabetic nephropathy? Journal of Pharmacy and Bioallied Sciences ddp4i diabetes progression diabetic nephropathy glucagon-like peptide-1 agonist newer antidiabetics peroxisome proliferator-activated receptors-γ sglt-2i |
| title | Can newer anti-diabetic therapies delay the development of diabetic nephropathy? |
| title_full | Can newer anti-diabetic therapies delay the development of diabetic nephropathy? |
| title_fullStr | Can newer anti-diabetic therapies delay the development of diabetic nephropathy? |
| title_full_unstemmed | Can newer anti-diabetic therapies delay the development of diabetic nephropathy? |
| title_short | Can newer anti-diabetic therapies delay the development of diabetic nephropathy? |
| title_sort | can newer anti diabetic therapies delay the development of diabetic nephropathy |
| topic | ddp4i diabetes progression diabetic nephropathy glucagon-like peptide-1 agonist newer antidiabetics peroxisome proliferator-activated receptors-γ sglt-2i |
| url | http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2021;volume=13;issue=4;spage=341;epage=351;aulast=Aziz |
| work_keys_str_mv | AT sohailaziz cannewerantidiabetictherapiesdelaythedevelopmentofdiabeticnephropathy AT sitimaisharahsheikhghadzi cannewerantidiabetictherapiesdelaythedevelopmentofdiabeticnephropathy AT syedazharsyedsulaiman cannewerantidiabetictherapiesdelaythedevelopmentofdiabeticnephropathy AT nurhafzanmdhanafiah cannewerantidiabetictherapiesdelaythedevelopmentofdiabeticnephropathy AT sabariahnoorharun cannewerantidiabetictherapiesdelaythedevelopmentofdiabeticnephropathy |